All News

Patients with multiple myeloma who are undergoing systemic treatment can see improvements from exercise, a recent study shows.

“Full-time mom, full-time hairdresser, full-time wife” Maggie Cambora, who received a diagnosis of acute myeloid leukemia in 2020, received a stem cell transplant.

The notion of ‘time toxicity’ causes patients with stage 4 melanoma to have less available time in their everyday lives because of appointments and treatments.

A phase 2 trial found that some patients with classical Hodgkin lymphoma saw a nearly 74% probability of second remission due to retreatment with Keytruda.

Battling the unforgiving foe: Cancer.

The PALLAS trial analyzed the impact of BMI in patients with early hormone receptor positive breast cancer.

The BRAF inhibitor AMB-1310 is currently being studied in both the United States and China for the treatment of patients with glioblastoma who are carrying the BRAF V600E mutation.

Treatment with the combination of Sarclisa, Kyprolis, Revlimid and Isa-KRd generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

Treatment combination of Lutathera and Sandostatin improved outcomes for patients with gastroenteropancreatic neuroendocrine tumors.

As part of its Speaking Out video series, CURE spoke with Marla Sustin, from University Hospitals Seidman Cancer Center, about personalized therapy in breast cancer care.

As part of its Speaking Out video series, CURE spoke with Marla Sustin, from University Hospitals Seidman Cancer Center, about side effect management in breast cancer care.

As part of its Speaking Out video series, CURE spoke with Marla Sustin, from University Hospitals Seidman Cancer Center, about prognostic and predictive outcomes in breast cancer, and the options available as a result.

As part of its Speaking Out video series, CURE spoke with Juanita Miller, an ANGEL Advocate from the Tigerlily Foundation, about fear of recurrence after breast cancer.

Summer came to an end after my cancer diagnosis.

A woman with stage 4 inflammatory breast cancer details her journey with the disease and why it is important for patients to ask questions about anything going on with their bodies.

Mezigdomide plus Velcade and dexamethasone or Kyprolis and dexamethasone showed promising response rates across multiple doses in patients with relapsed or refractory multiple myeloma, research showed.

Back 50 years or so ago, people didn’t discuss cancer freely. Today, things have changed.

As Connor McGregor honors a fan who dies from cancer and Steve Scalise reveals information about his blood cancer, this is what’s happening in the oncology space this week.

While much progress has been made in treating blood cancers like lymphoma, I know that there is still far more work to be done.

CURE looks back on some of the most important stories in the chronic lymphocytic leukemia space from 2023.

Tecentriq plus carboplatin and pemetrexed may improve efficacy in patients with NSCLC with untreated brain metastases, according to results of a phase 2 trial.

This is how I accepted that I am running out of time and options.

An expert discusses what patients can expect when being treated with the Hepzato kit, a direct-to-liver therapy for metastatic uveal melanoma.

Ashton’s story starts with her. Our beautiful, big-hearted, kind girl.

Patients with chronic lymphocytic leukemia treated with Imbruvica plus Venclexta demonstrated a healthy immune profile over time in addition to reduction in CLL disease burden.

When both a patient and their loved one acting as their caregiver are facing cancer, “there has to be proper care for both,” one expert tells CURE®.

The very first blog I ever wrote for CURE asked the question, “Why me?”

The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma.